Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim
Cancer Res Treat. 2022;54(2):469-477. Published online 2021 Jun 23 DOI: https://doi.org/10.4143/crt.2021.205
Citations to this article as recorded by 
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
Hélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Jean-Sébastien Frenel, Séverine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule
Cancers.2023; 15(4): 1191. CrossRef
Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
Mikhail V. Blagosklonny
Oncotarget.2023; 14(1): 193. CrossRef
A systematic review of computational approaches to understand cancer biology for informed drug repurposing
Faheem Ahmed, Anupama Samantasinghar, Afaque Manzoor Soomro, Sejong Kim, Kyung Hyun Choi
Journal of Biomedical Informatics.2023; 142: 104373. CrossRef
Tetraspanin 1 (TSPAN1) promotes growth and transferation of breast cancer cells via mediating PI3K/Akt pathway
Yange Wu, Wenxiu Chen, Yufeng Gong, Hongxia Liu, Bo Zhang
Bioengineered.2021; 12(2): 10761. CrossRef